This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.

This disclosure provides reagents and methods of predicting the responsiveness of a patient to NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates).

The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.

The invention provides a method for determining a systemic lupus erythematosus-associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table A, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table A is indicative of a systemic Lupus-associated disease state. The invention also provides an array and a kit suitable for use in the methods of the invention.

The invention relates to the detection of EGYR peptide in a biological sample as a measure of the presence and/or amount of LARP1 protein in the sample. Suitably, the invention relates to methods for quantitative measurement of LARP1 and LARP1-derived EGYR peptide by chromatography-tandem mass spectrometry. The invention also relates to peptide standards and their use in quantitative mass spectrometric analyses. The ability to detect the amount of LARP1 in a biological sample has application in detecting and monitoring cancer.

This disclosure describes markers that are associated with active tuberculosis (TB) and demonstrates that the disclosed markers can be used as a biomarker for determining whether a subject has or is at risk of having active TB and for the early detection of HIV-associated TB. This disclosure also provides methods of screening subjects who are thought to be at risk for developing active TB, methods of determining the efficacy of therapeutic regimens for preventing or treating active TB, and methods of identifying anti-TB agents.

The present invention relates to a method for quantifying an anti-TNF antibody in a sample of a human individual comprising a step of adding to a test sample which may contain therapeutic anti-TNF antibodies a known amount of two or more labeled forms of said anti-TNF antibodies.

Implant related risk of revision not caused by an infection or metal on metal reaction can be addressed by the methods provided herein, including diagnosing implant related risk of revision, use of kits for such diagnostic purposes and compositions for use in the treatment of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction.

The invention relates to a method for prognosing disease progression in a patient that has or is at risk of developing a severe acute respiratory syndrome (SARS), wherein the method comprises determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in a sample from the patient, wherein said level indicates the severity of SARS progression. The method is in some embodiments configured for use when a patient exhibits symptoms of a severe acute respiratory syndrome (SARS), a patient exhibits symptoms of infection with a SARS-virus, the patient is infected with a SARS-virus, such as a SARS-coronavirus, such as SARS-CoV2.

Provided is a model for evaluating the degree of liver fibrosis constructed based on bile acids. A plurality of bile acids are simultaneously detected by a liquid chromatography-tandem mass spectrometer to further improve the accuracy in combination with other liver indicators; moreover, a multiple regression analysis method is applied to establish a grading diagnosis model for the degree of liver fibrosis caused by a chronic liver disease, which can significantly improve the sensitivity and specificity of the existing non-invasive diagnosis of liver fibrosis. When the model is used to evaluate the degree of liver fibrosis of a patient, the highest AUC is up to 0.9278; the sensitivity is up to 86.79%; and the specificity is up to 89.01%. The detection results are completely consistent with the pathological results of clinical liver biopsy. Therefore, patients need not receive a liver biopsy.